The ability of compounds 76a–o to inhibit recombinant human HDAC1, HDAC3, and HDAC6 isoforms and ‘in vitro’ activity against cancer cell lines RMPI 8226 and HCT 116 was tested. This evidence concerns the gene HDAC3 and cancer.